Jeffrey Dierks - Aug 22, 2022 Form 4 Insider Report for Harmony Biosciences Holdings, Inc. (HRMY)

Role
CHIEF COMMERCIAL OFFICER
Signature
/s/ Christian Ulrich, Attorney-in-Fact
Stock symbol
HRMY
Transactions as of
Aug 22, 2022
Transactions value $
-$666,423
Form type
4
Date filed
8/23/2022, 04:11 PM
Previous filing
Apr 5, 2022
Next filing
Oct 4, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction HRMY Common Stock Options Exercise $695K +29K $24.00 29K Aug 22, 2022 Direct
transaction HRMY Common Stock Sale -$1.25M -26.7K -91.99% $46.95 2.32K Aug 22, 2022 Direct F1, F2
transaction HRMY Common Stock Sale -$110K -2.32K -100% $47.56 0 Aug 22, 2022 Direct F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction HRMY Stock Option Options Exercise $0 -29K -25% $0.00 86.9K Aug 22, 2022 Common Stock 29K $24.00 Direct F4, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.40 to $47.39. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $47.41 to $47.70. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4 The stock option vests in five equal annual installments beginning on August 21, 2021.
F5 The Form 4 filed by the reporting person on March 2, 2022, overstated the number of securities owned following the reported transaction by 200 shares. The amount of securities reported herein reflects the correct number of securities owned following the transactions reported on this Form 4.